{"title":"Meet the editor: Iván Pérez-Neri","authors":"I. Pérez-Neri","doi":"10.31157/an.vi.375","DOIUrl":"https://doi.org/10.31157/an.vi.375","url":null,"abstract":"","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76961226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Meet the Editor: Sergio A. Castillo-Torres","authors":"Sergio Andrés Castillo Torres","doi":"10.31157/an.vi.376","DOIUrl":"https://doi.org/10.31157/an.vi.376","url":null,"abstract":"","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74565644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-03DOI: 10.31157/an.v1iinpress.356
Pérez-Neri Iván, Estêvão M Dulce, M. Rakesh, Sandoval Hugo, Zárate Manuel, Ríos Camilo
Introduction: Each year, approximately 795,000 people experience a new or recurrent stroke, either ischemic or hemorrhagic. The current therapeutical approach for acute ischemic stroke includes thrombolysis and mechanical thrombectomy; still, no neuroprotective treatment options currently exist to improve its neurological outcome. Some components of the endocannabinoid system are altered after ischemic stroke. It is considered that cannabinoids may exert neuroprotective effects; however, the use of cannabinoid receptor ligands is a major concern due to its psychotropic properties. Regardless that there are many studies describing the benefit of administering cannabinoids for experimental stroke several unanswered questions remain since most of the information point up in non-human species. A previous systematic review detected significant heterogeneity among studies, so it is appropriate to perform a scoping review to evaluate the feasibility of performing an updated systematic review and meta-analysis. This scoping review aims to evaluate the therapeutic potential of modulating the endocannabinoid system for stroke. Methods: Published studies (all publication types) will be retrieved from Web of Science, PubMed, Scopus, Ovid, EBSCOhost, and Google Scholar. Eligibility criteria: Clinical or preclinical studies reporting endocannabinoid levels or their effects, or reporting administration of cannabinoid modulators (stimulating or inhibiting their synthesis or metabolism, phytocannabinoids, or synthetic cannabinoids), in patients or models of stroke will be considered for inclusion. Studies written in languages different than Spanish or English that could not be appropriately translated, or whose full-text files could not be retrieved will be excluded. Data charting: Results will be summarized in tabular form. This protocol complies with PRISMA-P.
简介:每年，大约有795,000人经历新的或复发性中风，无论是缺血性还是出血性。目前急性缺血性卒中的治疗方法包括溶栓和机械取栓;然而，目前还没有神经保护治疗方案来改善其神经预后。缺血性中风后，内源性大麻素系统的某些成分发生改变。大麻素被认为可能具有神经保护作用;然而，大麻素受体配体的使用是一个主要的问题，由于其精神药物的性质。尽管有许多研究描述了在实验性中风中使用大麻素的好处，但由于大多数信息都指向非人类物种，因此仍有几个未解决的问题。先前的系统综述发现研究之间存在显著的异质性，因此有必要进行范围综述，以评估进行更新的系统综述和荟萃分析的可行性。本综述旨在评估调节内源性大麻素系统对中风的治疗潜力。方法:已发表的研究(所有出版类型)将从Web of Science, PubMed, Scopus, Ovid, EBSCOhost和Google Scholar中检索。入选标准:临床或临床前研究报告内源性大麻素水平或其影响，或报告大麻素调节剂(刺激或抑制其合成或代谢，植物大麻素或合成大麻素)在中风患者或模型中的应用将被考虑纳入。用西班牙语或英语以外的语言撰写的研究，如果不能适当翻译，或者其全文文件无法检索，将被排除在外。数据图表:结果将以表格形式汇总。本协议遵循PRISMA-P。
{"title":"Therapeutic potential of cannabinoids for stroke: scoping review protocol","authors":"Pérez-Neri Iván, Estêvão M Dulce, M. Rakesh, Sandoval Hugo, Zárate Manuel, Ríos Camilo","doi":"10.31157/an.v1iinpress.356","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.356","url":null,"abstract":"Introduction: Each year, approximately 795,000 people experience a new or recurrent stroke, either ischemic or hemorrhagic. The current therapeutical approach for acute ischemic stroke includes thrombolysis and mechanical thrombectomy; still, no neuroprotective treatment options currently exist to improve its neurological outcome. Some components of the endocannabinoid system are altered after ischemic stroke. It is considered that cannabinoids may exert neuroprotective effects; however, the use of cannabinoid receptor ligands is a major concern due to its psychotropic properties. Regardless that there are many studies describing the benefit of administering cannabinoids for experimental stroke several unanswered questions remain since most of the information point up in non-human species. A previous systematic review detected significant heterogeneity among studies, so it is appropriate to perform a scoping review to evaluate the feasibility of performing an updated systematic review and meta-analysis. This scoping review aims to evaluate the therapeutic potential of modulating the endocannabinoid system for stroke. Methods: Published studies (all publication types) will be retrieved from Web of Science, PubMed, Scopus, Ovid, EBSCOhost, and Google Scholar. Eligibility criteria: Clinical or preclinical studies reporting endocannabinoid levels or their effects, or reporting administration of cannabinoid modulators (stimulating or inhibiting their synthesis or metabolism, phytocannabinoids, or synthetic cannabinoids), in patients or models of stroke will be considered for inclusion. Studies written in languages different than Spanish or English that could not be appropriately translated, or whose full-text files could not be retrieved will be excluded. Data charting: Results will be summarized in tabular form. This protocol complies with PRISMA-P.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87235597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-31DOI: 10.31157/an.v1iinpress.346
E. Morales, Camila Herrera, Ledys Montaño, Karin Martínez, M. Meza, Natalia Del Villar, Xilene Mendoza, Alexander Rodríguez
Introduction: Huntington's Disease (HD) is a hereditary, neurodegenerative disorder due to abnormal repeats of the CAG triplet in the IT-15 gene. It is characterized by a triad of progressive motor, psychiatric and cognitive symptoms, resulting from striatal neuronal loss. The impact of HD in Latin America is evidenced by the prevalence rates in Maracaibo (Venezuela) and Juan de Acosta (Colombia), which are the highest recorded in the world. This contrasts with the social abandonment and the scarce intervention of local governments. Aim: Provide an approach to the most relevant aspects of HD from its pathogenesis and associated genetic polymorphisms, to the current treatment options. Methodology: A literature review was performed of the state of the art of prognosis and treatment strategies in HD, including the identification of different polymorphic markers in the genes coding for UCHL1, HIP1, PGC1α, GRIK2, TBP, BDNF, among others, and its associations in the evolution of the disease in the presence of abnormal CAG repeats. Conclusion: Even though in the last decades many researchers have focused on the development of curative treatment, there is no effective therapeutic target to prevent the clinical onset of the disease or to delay its progression. Instead, current pharmacological management is palliative, the evidence to generalize the surgical approaches is insufficient. Newly, the fetal neural cell transplantation into the striatum is offered as the surgical option that provides hope for the development of a true disease-modifying treatment.
{"title":"Current Knowledge and Future Directions in Huntington’s Disease","authors":"E. Morales, Camila Herrera, Ledys Montaño, Karin Martínez, M. Meza, Natalia Del Villar, Xilene Mendoza, Alexander Rodríguez","doi":"10.31157/an.v1iinpress.346","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.346","url":null,"abstract":"Introduction: Huntington's Disease (HD) is a hereditary, neurodegenerative disorder due to abnormal repeats of the CAG triplet in the IT-15 gene. It is characterized by a triad of progressive motor, psychiatric and cognitive symptoms, resulting from striatal neuronal loss. The impact of HD in Latin America is evidenced by the prevalence rates in Maracaibo (Venezuela) and Juan de Acosta (Colombia), which are the highest recorded in the world. This contrasts with the social abandonment and the scarce intervention of local governments. \u0000Aim: Provide an approach to the most relevant aspects of HD from its pathogenesis and associated genetic polymorphisms, to the current treatment options. \u0000Methodology: A literature review was performed of the state of the art of prognosis and treatment strategies in HD, including the identification of different polymorphic markers in the genes coding for UCHL1, HIP1, PGC1α, GRIK2, TBP, BDNF, among others, and its associations in the evolution of the disease in the presence of abnormal CAG repeats. \u0000Conclusion: Even though in the last decades many researchers have focused on the development of curative treatment, there is no effective therapeutic target to prevent the clinical onset of the disease or to delay its progression. Instead, current pharmacological management is palliative, the evidence to generalize the surgical approaches is insufficient. Newly, the fetal neural cell transplantation into the striatum is offered as the surgical option that provides hope for the development of a true disease-modifying treatment.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"91 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81578123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-26DOI: 10.31157/an.v1iinpress.367
Sabino Luzzi
{"title":"Meet the Editor: Sabino Luzzi","authors":"Sabino Luzzi","doi":"10.31157/an.v1iinpress.367","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.367","url":null,"abstract":"","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"712 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76903842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-26DOI: 10.31157/an.v1iinpress.347
J. Suárez-Escudero, Karla Sofia Lema Porto, Daniela Palacio Patiño, Manuela Izquierdo Moreno, Claudia Liliana Bedoya Londoño
el acto de tragar va más allá de un fenómeno mecánico. Es un proceso altamente complejo, elaborado y modelado por varios niveles del sistema nervioso. Su alteración es consecuencia directa o complicación asociada de varias patologías, donde sobresale la disfagia orofaríngea por etiología funcional de origen neurológico y neuromuscular. Es objetivo actualizar el conocimiento sobre los fundamentos y concepto de la disfagia orofaríngea neurogénica, y proveer información de utilidad clínica de sus principales causas. Los trastornos neurológicos son responsables del 70% al 80% de la etiología de la disfagia orofaríngea. Se produce principalmente por el accidente cerebrovascular, enfermedad de Parkinson, esclerosis múltiple, esclerosis lateral amiotrófica y traumatismo encéfalo craneano. Conclusiones: La disfagia orofaríngea neurogénica resulta de lesiones en cualquier parte de los circuitos y estructuras centrales entre la corteza cerebral y los componentes periféricos de la deglución, y los déficits fisiológicos son variados. La comprensión conceptual, fisiopatológica y de características clínicas de las principales causas de disfagia neurogénica ayudan a los equipos asistenciales para realizar acciones de detección, diagnóstico, tratamiento y rehabilitación oportuna.
{"title":"Disfagia orofaríngea neurogénica: concepto, fisiopatología, clínica y terapéutica","authors":"J. Suárez-Escudero, Karla Sofia Lema Porto, Daniela Palacio Patiño, Manuela Izquierdo Moreno, Claudia Liliana Bedoya Londoño","doi":"10.31157/an.v1iinpress.347","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.347","url":null,"abstract":"el acto de tragar va más allá de un fenómeno mecánico. Es un proceso altamente complejo, elaborado y modelado por varios niveles del sistema nervioso. Su alteración es consecuencia directa o complicación asociada de varias patologías, donde sobresale la disfagia orofaríngea por etiología funcional de origen neurológico y neuromuscular. Es objetivo actualizar el conocimiento sobre los fundamentos y concepto de la disfagia orofaríngea neurogénica, y proveer información de utilidad clínica de sus principales causas. Los trastornos neurológicos son responsables del 70% al 80% de la etiología de la disfagia orofaríngea. Se produce principalmente por el accidente cerebrovascular, enfermedad de Parkinson, esclerosis múltiple, esclerosis lateral amiotrófica y traumatismo encéfalo craneano. Conclusiones: La disfagia orofaríngea neurogénica resulta de lesiones en cualquier parte de los circuitos y estructuras centrales entre la corteza cerebral y los componentes periféricos de la deglución, y los déficits fisiológicos son variados. La comprensión conceptual, fisiopatológica y de características clínicas de las principales causas de disfagia neurogénica ayudan a los equipos asistenciales para realizar acciones de detección, diagnóstico, tratamiento y rehabilitación oportuna.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"2007 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86208886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Appreciation to Reviewers 2021","authors":"Editorial Council","doi":"10.31157/an.vi.357","DOIUrl":"https://doi.org/10.31157/an.vi.357","url":null,"abstract":"","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87860748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-26DOI: 10.31157/an.v1iinpress.333
Cristopher Ramirez-Loera, Diego A. Sandoval-Lopez, S. Mejía-Pérez
Objective: To describe the case of a patient diagnosed with Neurofibromatosis Type 1 (NF1), who developed her first neoplastic lesion as Primary Central Nervous System Lymphoma (PCNSL). To our knowledge, this is the third case of PCNSL in the context of NF1. Background: PCNSL represents 1% of non-Hodgkin extranodal Lymphomas, and 3% of CNS tumors. Diffuse Large B-Cell Lymphoma accounts for 30-40% of the cases, commonly found in the encephalus, spinal cord, leptomeninges, or the eye. Predominant malignant tumors in NF1 are gliomas and Malignant Peripheral Nerve Sheath Tumor (MPNST). Methods: A 53-year-old Mexican female, with a history of NF1, arrived at the emergency department with left-side subacute progressive numbness and weakness. Left hemiplegia. MRI showed a ring-enhancing lesion in the right central lobe and a lesion in the subcutaneous tissue. Additionally, the patient underwent a full body 18-FDG PET scan, which reported activity only in the CNS. Results: Lesion-centered craniectomy and surgical evacuation were performed. Histopathological examination revealed lymphoid lineage cells, CD20, PAX-5, and Ki-67 were positive for neoplastic cells, confirming the diagnosis of PCNSL. At the 6-months follow-up visit, strength improved significantly, and the follow-up MRI did not show residual mass. Conclusions: It is necessary to study the prevalence of LPSNC in these patients, as well as the relative risk, and to develop guidelines for its best approach. We believe that the real incidence of the disease is underestimated, since the genetic and pathophysiological mechanisms that promote its origin still need to be clarified.
{"title":"Primary CNS Lymphoma of Diffuse B cells in a Patient with Neurofibromatosis Type 1: A Case Report.","authors":"Cristopher Ramirez-Loera, Diego A. Sandoval-Lopez, S. Mejía-Pérez","doi":"10.31157/an.v1iinpress.333","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.333","url":null,"abstract":"Objective: To describe the case of a patient diagnosed with Neurofibromatosis Type 1 (NF1), who developed her first neoplastic lesion as Primary Central Nervous System Lymphoma (PCNSL). To our knowledge, this is the third case of PCNSL in the context of NF1. \u0000Background: PCNSL represents 1% of non-Hodgkin extranodal Lymphomas, and 3% of CNS tumors. Diffuse Large B-Cell Lymphoma accounts for 30-40% of the cases, commonly found in the encephalus, spinal cord, leptomeninges, or the eye. Predominant malignant tumors in NF1 are gliomas and Malignant Peripheral Nerve Sheath Tumor (MPNST). \u0000Methods: A 53-year-old Mexican female, with a history of NF1, arrived at the emergency department with left-side subacute progressive numbness and weakness. Left hemiplegia. MRI showed a ring-enhancing lesion in the right central lobe and a lesion in the subcutaneous tissue. Additionally, the patient underwent a full body 18-FDG PET scan, which reported activity only in the CNS. \u0000Results: Lesion-centered craniectomy and surgical evacuation were performed. Histopathological examination revealed lymphoid lineage cells, CD20, PAX-5, and Ki-67 were positive for neoplastic cells, confirming the diagnosis of PCNSL. At the 6-months follow-up visit, strength improved significantly, and the follow-up MRI did not show residual mass. \u0000Conclusions: It is necessary to study the prevalence of LPSNC in these patients, as well as the relative risk, and to develop guidelines for its best approach. We believe that the real incidence of the disease is underestimated, since the genetic and pathophysiological mechanisms that promote its origin still need to be clarified.","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84267383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-26DOI: 10.31157/an.v1iinpress.344
Diana Paola Duarte Mora, Paula Valentina Palacino Domínguez, Luis Orlando Rojas Romero
RESUMEN Introducción: La cirugía estereotáctica es una técnica quirúrgica con múltiples aplicaciones diagnósticas y terapéuticas que permite al neurocirujano realizar procedimientos más precisos y menos invasivos en comparación con la cirugía convencional, con el fin de evitar lesionar áreas funcionales. Metodología: Se realizó un estudio descriptivo retrospectivo de corte transversal en el cual se revisaron las historias clínicas de los pacientes mayores de 18 años intervenidos quirúrgicamente por medio de cirugía estereotáxica entre enero de 2000 y diciembre de 2020 en el Hospital Militar Centra (Bogotá, Colombia) Resultados: En el periodo de estudio comprendido entre enero del año 2000 y diciembre del año 2020 se encontraron un total de 119 pacientes intervenidos por medio de estereotaxia con objetivos diagnósticos y terapéuticos, de los cuales 44 son mujeres y 75 son hombres. La mayoría de los pacientes fueron llevados a resección y biopsia de tumores intracraneales. Se obtuvo una tasa de complicaciones del 4,2%. Conclusiones: La cirugía estereotáctica es una técnica quirúrgica útil en el diagnóstico y tratamiento de diversas patologías que tiene buen rendimiento diagnóstico y baja tasa de complicaciones. En el presente estudio se presentan tasas de complicaciones similares a las reportadas en la literatura mundial siendo esta serie la única que analiza los resultados obtenidos con esta técnica quirúrgica en la población de las Fuerzas Militares de Colombia
{"title":"Experiencia cirugía estereotáctica entre los años 2000 y 2020 en el Hospital Militar Central, Bogotá, Colombia","authors":"Diana Paola Duarte Mora, Paula Valentina Palacino Domínguez, Luis Orlando Rojas Romero","doi":"10.31157/an.v1iinpress.344","DOIUrl":"https://doi.org/10.31157/an.v1iinpress.344","url":null,"abstract":"RESUMEN \u0000Introducción: La cirugía estereotáctica es una técnica quirúrgica con múltiples aplicaciones diagnósticas y terapéuticas que permite al neurocirujano realizar procedimientos más precisos y menos invasivos en comparación con la cirugía convencional, con el fin de evitar lesionar áreas funcionales. \u0000Metodología: Se realizó un estudio descriptivo retrospectivo de corte transversal en el cual se revisaron las historias clínicas de los pacientes mayores de 18 años intervenidos quirúrgicamente por medio de cirugía estereotáxica entre enero de 2000 y diciembre de 2020 en el Hospital Militar Centra (Bogotá, Colombia) \u0000Resultados: En el periodo de estudio comprendido entre enero del año 2000 y diciembre del año 2020 se encontraron un total de 119 pacientes intervenidos por medio de estereotaxia con objetivos diagnósticos y terapéuticos, de los cuales 44 son mujeres y 75 son hombres. La mayoría de los pacientes fueron llevados a resección y biopsia de tumores intracraneales. Se obtuvo una tasa de complicaciones del 4,2%. \u0000Conclusiones: La cirugía estereotáctica es una técnica quirúrgica útil en el diagnóstico y tratamiento de diversas patologías que tiene buen rendimiento diagnóstico y baja tasa de complicaciones. En el presente estudio se presentan tasas de complicaciones similares a las reportadas en la literatura mundial siendo esta serie la única que analiza los resultados obtenidos con esta técnica quirúrgica en la población de las Fuerzas Militares de Colombia","PeriodicalId":34902,"journal":{"name":"Archivos de Neurociencias","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81167414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：